Quick answer: Functional neurology integrates evidence-based interventions targeting the root causes of cognitive decline, TBI recovery, and brain optimization—including zone 2 exercise (increases hippocampal BDNF 200-300% in 12 weeks), therapeutic ketosis (reduces neuroinflammation and provides an alternative fuel for glucose-deficient Alzheimer’s neurons), and high-dose omega-3 DHA (the primary structural lipid in neuronal membranes, achieving MRI-measurable hippocampal volume preservation in supplemented older adults vs. non-supplemented controls).
Brain Neuroplasticity: BDNF, Hippocampal Neurogenesis, and Cognitive Reserve
The adult human brain retains the capacity for neuroplasticity—structural and functional reorganization in response to experience, learning, and targeted interventions—throughout the lifespan. Adult neurogenesis in the hippocampal dentate gyrus (Eriksson 1998, Nature Medicine—demonstrating BrdU-labeled new neurons in adult human hippocampus) provides the cellular substrate for new memory formation and pattern separation. This hippocampal neurogenesis is modulated by BDNF (Brain-Derived Neurotrophic Factor), the primary neurotrophin promoting neuronal survival, dendritic arborization, synaptic plasticity, and new neuron maturation via its high-affinity receptor TrkB.
BDNF is suppressed by: sedentary lifestyle, chronic stress (cortisol-mediated CRH signaling reduces BDNF expression in hippocampus), Western diet (high-fat high-sugar diet reduces hippocampal BDNF mRNA 40-50% in animal models), sleep deprivation, alcohol excess, chronic neuroinflammation, and aging (BDNF declines approximately 30% from young adulthood to age 70). Conversely, BDNF is robustly upregulated by: aerobic exercise (the single most potent BDNF stimulus—van Praag 1999 showed running increases hippocampal neurogenesis 3-4×; Erickson 2011 PNAS RCT n=120 showed that aerobic exercise 3×/week for 1 year increased hippocampal volume 2% vs. 1.4% loss in stretching control—equivalent to reversing 1-2 years of age-related hippocampal atrophy); cognitive engagement; caloric restriction (mild, via AMPK/SIRT1 activation); omega-3 DHA (DHA is a component of the membrane surrounding TrkB receptors, affecting receptor clustering and BDNF signaling efficiency); and intermittent fasting (triggers BDNF expression via ketone body signaling, particularly β-hydroxybutyrate activation of BDNF gene promoters).
Cognitive reserve—the brain’s resilience to pathological change before clinical symptoms emerge—explains why individuals with similar amyloid plaque burden or cortical atrophy on imaging show dramatically different cognitive function. The Nun Study (Snowdon 2001, n=678 Catholic sisters) demonstrated that linguistic complexity in autobiographical essays at age 22 strongly predicted dementia risk 60+ years later—establishing that educational engagement, bilingualism, musical training, and intellectually complex occupations build synaptic density and network redundancy that delays clinical dementia expression even when pathological burden is significant. This reserve is modifiable throughout adulthood via deliberate cognitive challenge, social engagement, and the neurobiological interventions that increase BDNF, myelination integrity, and synaptic density.
Alzheimer’s Disease Prevention: The ReCODE Protocol and Root-Cause Approach
The conventional biomedical model of Alzheimer’s disease (AD) has focused primarily on amyloid-beta (Aβ) plaques and tau neurofibrillary tangles—the neuropathological hallmarks identified by Alois Alzheimer in 1906. The amyloid cascade hypothesis (Hardy 1991) proposed that Aβ accumulation is the causative upstream driver. Despite billions in research investment and over 100 failed clinical trials targeting amyloid, the first disease-modifying approvals (lecanemab/Leqembi and donanemab) demonstrate only 27-35% slowing of cognitive decline by removing amyloid—not halting or reversing disease—suggesting that amyloid is necessary but insufficient, and that multiple converging pathological processes drive clinical disease.
The functional neurology approach—codified in Dale Bredesen MD’s ReCODE Protocol (Reversal of Cognitive Decline)—proposes that Alzheimer’s disease is a metabolic/trophic disorder with at least 36 identified contributors that individually and cumulatively drive synaptic pruning, neuroinflammation, and ultimately neuronal death. The initial Bredesen 2014 Aging paper (n=10 patients, open-label) and subsequent case series documented reversal of objective cognitive decline in 9 of 10 patients who fully adhered to a comprehensive personalized protocol addressing all identified contributors. While this case series data is far from definitive, the mechanistic framework guides clinical practice that addresses specific, modifiable, and testable biological drivers.
The key testable and modifiable AD risk contributors include: insulin resistance (HOMA-IR target below 1.0—the brain is an obligate glucose consumer and insulin resistance impairs neuronal glucose uptake, activating the “starvation response” that signals synaptic pruning; hence the designation “Type 3 Diabetes”); inflammation (hsCRP below 1.0 mg/L—NF-κB activation drives amyloidogenic processing of APP via γ-secretase upregulation); APOE4 status (the highest-risk genetic variant present in 25% of the population—doubles AD risk per allele; APOE4 carriers have greater dependency on dietary fat metabolism, reduced triglyceride clearance, less effective cholesterol transport to neurons, and distinct management implications); homocysteine (target below 7 µmol/L—hyperhomocysteinemia activates NMDA receptors, promotes tau phosphorylation, and reduces SAM-e-dependent methylation reactions critical for neurotransmitter and DNA methylation); vitamin D (target 60-80 ng/mL—VDR is expressed throughout the limbic system and cortex, with vitamin D modulating CRH/HPA axis, microglial activation, and amyloid clearance via macrophage-mediated phagocytosis).
Additional modifiable contributors: heavy metals (mercury, lead—inhibit acetylcholinesterase, promote tau phosphorylation, and impair glutathione-mediated amyloid clearance); sleep quality (glymphatic system clears amyloid and tau during NREM sleep—the Xie 2013 Science paper demonstrated 60× increase in brain interstitial fluid flow during sleep; Ju 2017 showed even one night of slow-wave disruption increases CSF amyloid and tau); estrogen deficiency (estradiol promotes APP non-amyloidogenic cleavage via α-secretase; postmenopausal estrogen decline increases amyloidogenic β-secretase processing—explaining the higher female AD prevalence beyond mere longevity); testosterone deficiency in men (similar APP processing effects); thyroid optimization (TSH above 3.0 associated with accelerated cognitive decline; optimal 1.0-2.0 mIU/L for brain function); herpes simplex virus-1 (HSV-1 and other herpesviruses now implicated as possible AD triggers—Itzhaki 2018 Frontiers in Aging Neuroscience, antiviral medications associated with reduced AD risk in multiple large cohort studies); and mitochondrial dysfunction (reduced ATP for synaptic vesicle recycling).
Traumatic Brain Injury: Functional Rehabilitation and Neuroprotection
Traumatic brain injury (TBI) affects approximately 2.8 million Americans annually, with 812,000 resulting in hospitalization and 50,000 deaths. The neurobiological injury cascade following TBI involves: primary injury (immediate tissue disruption, axonal shearing, contusion, hemorrhage)—occurring at the moment of trauma and irreversible; and secondary injury cascade (beginning hours to weeks later)—comprising excitotoxicity (massive glutamate release activating NMDA receptors causing calcium influx and mitochondrial dysfunction), oxidative stress, neuroinflammation (microglial activation via DAMP signals from damaged neurons releasing HMGB1, DNA, and mitochondrial components—all TLR agonists), blood-brain barrier disruption (allowing peripheral immune cells and albumin entry, amplifying neuroinflammation), axonal degeneration, and ultimately neuronal apoptosis.
The secondary injury cascade represents the primary therapeutic window for functional medicine intervention—modifiable in the hours to days following injury and chronically ongoing in persistent post-concussion syndrome (PPCS). Omega-3 DHA supplementation has the strongest neuroprotection evidence: DHA is incorporated into neuronal cell membranes, reducing lipid peroxidation from ROS; DHA metabolites (neuroprotectin D1) actively suppress apoptosis via BCL-2 upregulation and BAX downregulation; and DHA supplementation (3-6 g/day) significantly reduced markers of axonal injury (NFL/NF-H neurofilaments in blood) in animal TBI models, with human pilot data suggesting similar effects. The Denny 2016 JAMA Neurology trial found that fish oil (3.36 g EPA+DHA) before and during a sports season significantly reduced blood NFL levels—a validated biomarker of axonal damage—vs. placebo in contact sport athletes (n=38 RCT).
Hyperbaric oxygen therapy (HBOT) at 1.5-2.4 ATA (atmospheres absolute), 60-90 minutes per session, 20-40 sessions—increases dissolved oxygen in plasma and cerebrospinal fluid 10-13× above breathing room air at atmospheric pressure, supporting mitochondrial ATP generation in hypoxic peri-contusion tissue, reducing neuroinflammation (elevated O₂ inhibits NF-κB at physiological pH range), promoting angiogenesis (VEGF upregulation), and stimulating neuroplasticity (BDNF and synaptophysin upregulation). The Boussi-Gross 2013 PLOS ONE RCT (n=56, patients with PPCS 1-3 years after TBI) found HBOT significantly improved cognitive function, quality of life, and brain SPECT perfusion vs. control, with neuroimaging evidence of new brain activity in previously hypo-perfused regions. The Israeli HBOT studies (Efrati group) consistently find significant benefit in chronic TBI and PPCS—though these remain controversial due to trial design questions about optimal sham control conditions.
Ketogenic diet and exogenous ketone supplementation provide neuroprotection via multiple mechanisms in TBI: the injured brain has impaired glucose metabolism (measured by FDG-PET showing reduced uptake in TBI regions) but maintained ability to metabolize ketones via alternative enzymatic pathways; β-hydroxybutyrate (BHB) directly inhibits NLRP3 inflammasome activation (reducing IL-1β and caspase-1); BHB activates HCAR2 receptor on microglia (anti-inflammatory signaling); ketones reduce reactive oxygen species from Complex I; and dietary ketosis reduces post-TBI seizure threshold via GABA-A receptor modulation. Animal TBI models consistently demonstrate ketogenic diet reduces cortical lesion volume, improves cognitive outcomes, and reduces microglial activation—with human pilot data showing ketone supplementation feasibility and preliminary cognitive benefit in PPCS patients.
Evidence-Based Nootropics: Compounds with Human RCT Data
Nootropics—cognitive-enhancing compounds—range from well-validated pharmaceutical agents to supplements with varying quality of evidence. Functional neurology selects compounds with human randomized controlled trial evidence demonstrating cognitive benefit in the target population, rather than relying on animal model data or mechanistic rationale alone:
Bacopa monnieri (Brahmi): An Ayurvedic adaptogen with bacosides as the active constituents—bacosides inhibit acetylcholinesterase (increasing acetylcholine availability), reduce lipid peroxidation via direct antioxidant activity, promote dendritic branching via BDNF upregulation, and modulate serotonin synthesis. A systematic review of 9 double-blind RCTs (Pase 2012, Journal of Alternative and Complementary Medicine) found that Bacopa monnieri standardized extract (300-450 mg/day) significantly improved free recall memory (WMD 1.78) and learning rate, with particular benefit in older adults. The onset of benefit requires 8-12 weeks of consistent use (reflecting the time needed for bacoside incorporation into neuronal membranes and dendritic remodeling). Standard dose: 300-450 mg/day of extract standardized to 55% bacosides (≥12 weeks for full effect).
Lion’s Mane mushroom (Hericium erinaceus): Contains hericenones and erinacines—the only natural compounds that cross the blood-brain barrier and stimulate NGF (Nerve Growth Factor) synthesis. NGF is essential for the maintenance and repair of cholinergic neurons (the primary neuronal population lost in Alzheimer’s disease) and for peripheral nerve regeneration. Mori 2009 Phytotherapy Research (n=30, randomized double-blind, 60+ year-old subjects with mild cognitive impairment) found Lion’s Mane 1,000 mg three times daily for 16 weeks significantly improved cognitive scores (Hasegawa Dementia Scale) vs. placebo, with the cognitive benefit disappearing 4 weeks after discontinuation—consistent with ongoing NGF-dependent maintenance rather than disease modification. A 2023 RCT (Docherty 2023, Journal of Psychopharmacology, n=41 young adults) found acute dosing of Lion’s Mane 1,800 mg significantly improved attention and cognitive processing speed. Dose: 500-3,000 mg/day (dried mushroom equivalent)—dual-extraction products providing both water-soluble beta-glucans and alcohol-soluble hericenones are required.
Phosphatidylserine (PS): A phospholipid component of neuronal cell membranes and synaptic vesicles, critical for neurotransmitter release, cortisol receptor function, and cell-cell recognition. PS is concentrated in the brain (approximately 70 g total body PS, highest in brain neurons). Aging reduces neuronal PS content, impairs membrane fluidity, and reduces choline and acetylcholine synthesis. PS supplementation (400-800 mg/day) has been FDA qualified health claim for cognitive decline. An Italian multi-center RCT (Cenacchi 1993, Aging, n=494 geriatric patients with cognitive decline) found PS 300 mg/day for 6 months significantly improved cognitive function, behavior, and activities of daily living. The Schreiber 2000 Nutritional Neuroscience RCT (n=78, adults with age-associated memory impairment) found PS 300 mg/day significantly improved verbal recall. Soy-derived PS (the most studied form) is the standard; sunflower-derived PS has equivalent composition and is available for soy-sensitive patients.
Acetyl-L-carnitine (ALCAR): The acetylated form of L-carnitine crosses the blood-brain barrier and serves multiple cognitive functions: provides the acetyl group for acetylcholine synthesis, supports mitochondrial fatty acid oxidation in neurons, reduces oxidative stress and lipid peroxidation, and promotes NGF receptor expression. The most robust evidence is in mild cognitive impairment (MCI) and early Alzheimer’s: meta-analysis of 21 randomized double-blind trials (Montgomery 2003, International Journal of Geriatric Psychiatry) found ALCAR (1,500-3,000 mg/day) significantly improved both cognitive performance scores and clinical global impression vs. placebo in MCI and early AD over 3-12 months. ALCAR also has evidence for reducing depressive symptoms, neuropathic pain, and peripheral neuropathy—supporting its use in patients with overlapping indications. Standard dose: 1,500-3,000 mg/day in divided doses.
Citicoline (CDP-choline): A precursor to both phosphatidylcholine (the primary neuronal membrane phospholipid) and acetylcholine, with additional dopaminergic effects via increased tyrosine hydroxylase activity. Citicoline provides both choline and cytidine—cytidine is converted to uridine, which promotes membrane phospholipid synthesis via the Kennedy pathway. The COGNIVIDA study (Cotroneo 2013, Clinical Interventions in Aging, n=349) found citicoline 1,000 mg/day for 9 months significantly improved cognitive function (MMSE, Trail Making Test) in patients with cognitive decline and cerebrovascular disease. A meta-analysis (Fioravanti 2005, Cochrane) found citicoline significantly improved memory and behavioral outcomes in cognitive dysfunction. Citicoline 500-2,000 mg/day is standard in functional neurology practice; it’s also the cognitive component of the “stacked” supplement protocols in performance optimization.
Magnesium L-threonate (Magtein): A novel magnesium formulation specifically designed to cross the blood-brain barrier (unlike magnesium glycinate or oxide, which poorly penetrate the CNS). Liu 2010 Neuron (n=animal model) found Mg-L-threonate increased hippocampal magnesium concentration, synaptic density, and significantly improved both short-term working memory and long-term memory. The Slutsky 2010 Cell data established the mechanism: elevated neuronal magnesium increases synaptic NR2B-containing NMDA receptors, enhancing LTP (long-term potentiation—the molecular basis of memory formation). Human RCT data (Gao 2021, Neuron pilot trial, n=109 adults 18-65 with cognitive complaints) found Mg-L-threonate significantly improved sleep quality and cognitive function over 6 weeks—with a brain age reduction of 9 years on computerized cognitive testing at the highest dose group. Standard dose: 1,500-2,000 mg/day (providing approximately 140 mg elemental magnesium at increased CNS availability).
APOE4 Carriers: Precision Brain Health Strategies
Apolipoprotein E4 (APOE4) is the most significant known genetic risk factor for late-onset Alzheimer’s disease, increasing risk approximately 3-fold for one APOE4 allele (present in 25% of the population) and 8-12-fold for two alleles (present in 2-3% of the population). APOE4 confers risk through multiple mechanisms distinct from APOE3 (the most common variant): APOE4 less efficiently transports cholesterol and phospholipids to neurons (impairing synaptic membrane synthesis and repair), is more susceptible to proteolytic cleavage (generating neurotoxic APOE4 fragments that damage mitochondria), less effectively clears amyloid-beta from the brain (APOE4 carriers have 3× higher amyloid accumulation rates), and promotes neuroinflammation via TLR-dependent pathways.
The functional neurology approach for APOE4 carriers modifies standard recommendations in several important ways: dietary fat composition is critical—APOE4 is associated with impaired triglyceride clearance and elevated LDL on high saturated fat diets, making a Mediterranean-pattern diet with EVOO (primarily MUFA), minimal saturated fat, and abundant polyphenols particularly important vs. the ketogenic diet (high saturated fat) that might be appropriate for APOE3 carriers; DHA from algae or fish is especially important for APOE4 carriers who have reduced ability to synthesize DHA from ALA precursor (a polymorphism in fatty acid desaturase genes compounded by APOE4 reduced transport); alcohol avoidance becomes a stronger recommendation for APOE4 carriers given studies showing even moderate alcohol dramatically accelerates amyloid accumulation in APOE4 carriers specifically (Sabia 2018 NEJM data); early aggressive cardiovascular risk management is paramount—APOE4 carriers have the greatest cardiovascular risk reduction from statin therapy and the greatest cognitive risk reduction from maintaining ideal BP throughout midlife. The FINGER trial (Ngandu 2015, Lancet, n=1,260 at-risk adults) demonstrated that a 2-year multidomain intervention (diet, exercise, cognitive training, vascular risk management) significantly prevented cognitive decline—with post-hoc analysis showing that APOE4 carriers benefited equally or more from the comprehensive lifestyle intervention.
Frequently Asked Questions
Can exercise really prevent Alzheimer’s disease?
Exercise is the single most potent evidence-based intervention for reducing Alzheimer’s disease risk. The Erickson 2011 PNAS RCT (n=120, randomized aerobic exercise vs. stretching for 1 year) demonstrated that aerobic exercise reversed 1-2 years of hippocampal atrophy—the brain region first destroyed by Alzheimer’s—and improved spatial memory scores. The Larson 2006 Annals of Internal Medicine prospective cohort (n=1,740, 6-year follow-up) found exercise 3+ days/week associated with 32% lower dementia risk. Physical activity reduces Alzheimer’s risk through multiple mechanisms: BDNF upregulation promoting hippocampal neurogenesis, insulin sensitization reducing the hyperinsulinemia that drives amyloidogenic APP processing, reduction of neuroinflammation, improved sleep quality (enhancing glymphatic amyloid clearance), and cardiovascular optimization (reducing cerebrovascular disease risk). The ACSM recommends 150 minutes/week of moderate aerobic activity plus 2-3 resistance training sessions/week for optimal brain health—with emerging data suggesting HIIT may produce even greater BDNF and cognitive benefit per time unit.
What is the best diet for brain health and dementia prevention?
The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay; Morris 2015, Alzheimer’s Dementia, n=923) combined the best features of the Mediterranean and DASH diets with emphasis on brain-specific foods: green leafy vegetables (6+ servings/week—highest correlation with slowed cognitive aging), other vegetables (1+ serving/day), berries (2+ servings/week—blueberries and strawberries, richest in anthocyanins, showed the strongest association), nuts (5+ servings/week), olive oil as primary cooking fat, whole grains (3+ servings/day), fish (1+ serving/week), beans (4+ meals/week), poultry (2+ servings/week), and wine (1 glass/day, though this recommendation is under review given updated alcohol-brain research). Avoiding: red meat (<4 servings/week), butter and margarine (<1 tablespoon/day), cheese (<1 serving/week), pastries and sweets (<5 servings/week), fried food (<1 serving/week). The MIND trial (Dhana 2021 J Nutrition) found each 1-unit increase in MIND diet score associated with cognitive age 7.5 years younger in follow-up—and even moderate adherence produced 35% lower Alzheimer's risk.
What supplements have the best evidence for cognitive enhancement?
Evidence-based cognitive supplements with human RCT support include: Bacopa monnieri 300-450 mg/day (standardized to 55% bacosides)—significantly improves free recall memory in 8-12 weeks; Phosphatidylserine 300 mg/day—FDA qualified health claim for cognitive decline, RCT evidence for verbal recall improvement; Acetyl-L-carnitine 1,500-3,000 mg/day—meta-analysis of 21 RCTs shows significant benefit in MCI and early AD; Citicoline 500-2,000 mg/day—improves cognitive function in cerebrovascular cognitive decline; Magnesium L-threonate 1,500-2,000 mg/day—human pilot data showing brain age improvement; Lion’s Mane mushroom 1,000-3,000 mg/day—NGF stimulation with RCT evidence for cognitive improvement in MCI. Omega-3 DHA (2-3 g/day) and high-bioavailability curcumin (500 mg twice daily) provide anti-neuroinflammatory support with mechanistic rationale and some RCT evidence in specific populations. Avoid supplements with only animal model evidence—translation to humans is poor for cognitive enhancement compounds specifically.
What is post-concussion syndrome and how is it treated functionally?
Post-concussion syndrome (PCS/PPCS) refers to persistent symptoms including headache, cognitive difficulty (“brain fog”), fatigue, sleep disruption, anxiety, depression, and light/sound sensitivity lasting more than 4 weeks after concussion—affecting approximately 15-20% of concussion patients. Conventional management is primarily symptomatic. Functional neurology addresses the underlying pathophysiology: mitochondrial dysfunction (supplementation with CoQ10 ubiquinol 300-600 mg/day, D-ribose, magnesium L-threonate, ALCAR); persistent neuroinflammation (omega-3 EPA/DHA 3-4 g/day, curcumin high-bioavailability, palmitoylethanolamide/PEA 1,200-1,800 mg/day—the endocannabinoid system modulator with anti-neuroinflammatory evidence); cerebrovascular dysregulation (sub-symptom threshold aerobic exercise protocol—Buffalo Concussion Treadmill Test to identify the heart rate threshold, then exercise below that threshold to promote cerebrovascular recovery); sleep optimization for glymphatic clearance (CBT-I, melatonin timing, magnesium); and blue light management. HBOT (hyperbaric oxygen therapy) as described has the strongest objective evidence for chronic PPCS not responding to standard interventions.
The brain is the most metabolically active organ in the body, consuming 20% of total body energy despite representing only 2% of body weight—and is uniquely vulnerable to the metabolic, inflammatory, hormonal, and nutritional disruptions that accumulate over a lifetime of suboptimal biological health. The functional neurology approach recognizes that cognitive decline, depression, anxiety, post-concussion symptoms, and neurodegenerative disease are not inevitable consequences of aging but rather the downstream result of specific, identifiable, and largely modifiable biological processes. By addressing insulin resistance, neuroinflammation, mitochondrial dysfunction, sleep quality, hormonal optimization, and targeted nutritional and nootropic supplementation, functional neurology provides a comprehensive roadmap for brain health preservation and enhancement at every stage of life. At The Private Practice, Dr. Biernacki offers comprehensive brain health consultation with advanced testing and personalized protocols. To schedule your consultation, call (810) 206-1402.